Iroko Pharmaceuticals Makes Strategic Additions to Executive Team with Appointment of Clarence L. Young, M.D. as Chief Medical Officer and Moji James as General Counsel
4/18/2012 10:06:14 AM
PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC announces two key additions to its management team, Clarence L. Young, M.D., as Chief Medical Officer and Moji James as General Counsel and Vice President. Dr. Young will lead Iroko’s extensive clinical programs for the company’s investigational nonsteroidal anti-inflammatory drugs (NSAID) and Ms. James will oversee Iroko’s legal and compliance activities. Both Dr. Young and Ms. James will report to John Vavricka, President and Chief Executive Officer (CEO) of Iroko Pharmaceuticals.
comments powered by